(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






2 Result: CorMedix

CorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study

July 17th, 2015

Strategic Process Now Focused On Identifying Product Development & Commercialization Partners; Seeking Successor CEO to Drive Clinical Development; To Report Second Quarter 2015 Results; Company to Host Second Quarter Conference Call at 9:00 a.m. EDT. Read more

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix, Inc. - CRMD

June 30th, 2015

NEW YORK, NY / CRWEPRESSRELEASE / June 30, 2015 / Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NYSEMKT: CRMD). Such investors are advised to contact Robert S. Willoughby at rswilloughby. Read more

Load More Content

News By Industries